

Alain Herrera, MD, PhD, is currently Senior Consultant in Oncology. He has created Alain Oncology Consulting (AOC) in November 2008 after heading for ten years the Oncology business at Sanofi where he was successively Vice President responsible for Global Oncology Business Strategy and Development (2007-2008) and Head of Global Oncology Franchise (1998-2007) and contributed to the worldwide registration of oxaliplatin (ELOXATIN®) and rasburicase (FASTURTEC®/ELITEK®) as well as the Gastric and Head & Neck indications for docetaxel (TAXOTERE®).

Since 2008, he has worked with several companies in Europe, US and Asia being primarily involved in clinical development strategy, pipeline evaluation, product launch and positioning, partnerships.

He is an independent member of several Supervisory Boards / Boards of Directors including Nanobiotix, IDDI, PDcline Pharma, Gustave Roussy-Transfert, Arcad Foundation.

His previous responsibilities within Pharmaceutical industry include the roles of Chairman of Chiron Therapeutics Europe, Director of Chiron B.V, Corporate Vice President and Member of Management Council of Chiron Corporation and Managing Director at Pierre Fabre Oncology Laboratories.

Besides these duties, Dr. Herrera has also been since 1991 Hematologist Consultant at Antoine Beclere Hospital. He also used to be Senior Resident, assistant to Prof. Pierre Boivin (Beaujon Hospital/University Paris VII).

Dr. Herrera has published and lectured extensively as an invited speaker at national and international meetings on cancers. He has authored a lot of original manuscripts in addition to contributing to numerous review articles and book chapters.

He is an active member of ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology).